Andy Czysz

Andy Czysz currently serves as the Senior Medical Director of Clinical Development at MapLight Therapeutics, Inc., leading the indication for ML-007 in Schizophrenia since November 2023. Previous experience includes roles as Senior Medical Director Consultant, Senior Medical Director, and Medical Director of Clinical Development at Sage Therapeutics from October 2021 to April 2024. Prior to that, Andy Czysz was an Assistant Professor of Psychiatry at The University of Texas Southwestern Medical Center at Dallas from July 2019 to October 2021. A Psychiatry Resident in the Research Track at the University of Texas Southwestern from June 2015 to June 2019 and a participant in the Medical Scientist Training Program at the University of Illinois at Chicago from June 2007 to May 2015, Andy Czysz holds an MD and a PhD in Neuroscience from the University of Illinois Chicago, as well as a B.S. in Chemistry and Psychology from the University of Florida.